But what do you really expect when you’re invested in high risk molecular science nano chemistry. There’s nothing easy about it. Drug development is notoriously fickle anyway. It amuses me how some act so surprised and carry on like children when a drug is terminated or suffers some setback or hurdle when that’s speculative biopharma 101.
- Forums
- ASX - By Stock
- SPL
- Ann: DEP outperforms leading treatments in ovarian cancer model
Ann: DEP outperforms leading treatments in ovarian cancer model, page-12
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.1¢ |
Change
-0.001(0.55%) |
Mkt cap ! $37.52M |
Open | High | Low | Value | Volume |
9.0¢ | 9.1¢ | 9.0¢ | $47.58K | 525.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49413 | 9.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.2¢ | 22000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49413 | 0.091 |
1 | 2750 | 0.090 |
2 | 97420 | 0.089 |
1 | 5000 | 0.088 |
1 | 73255 | 0.087 |
Price($) | Vol. | No. |
---|---|---|
0.092 | 22000 | 1 |
0.093 | 30790 | 3 |
0.094 | 106393 | 1 |
0.099 | 1285 | 1 |
0.100 | 112106 | 4 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online